A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

NCT04663204 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Immunoglobulin A Nephropathy
Kidney Diseases
Glomerulonephritis, IGA
Glomerulonephritis
Autoimmune Diseases
Immune System Diseases

Interventions

DRUG: Sparsentan

Sponsor

University of Leicester

Collaborators

[object Object]